Enieni Okoya
Psychiatric/Mental Health · Norman, OKNPI 1477751196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 35.7% of the total. Reporting peaked in 2024 at $1,335 and has fallen 63.9% since, to $482 in 2025.
Across 163 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$694
- Otsuka America Pharmaceutical, Inc.$552
- Teva Pharmaceuticals USA, Inc.$446
- Alkermes, Inc.$361
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$319
- plus $750 from 10 others
What the payments were for
- Food & beverage$4,855100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 54 | $1,732 |
| AbbVie | 38 | $694 |
| Otsuka America Pharmaceutical, Inc. | 15 | $552 |
| Teva Pharmaceuticals USA, Inc. | 10 | $446 |
| Alkermes, Inc. | 8 | $361 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $319 |
| Indivior Inc. | 11 | $184 |
| Lundbeck LLC | 8 | $181 |
| Acadia Pharmaceuticals Inc | 3 | $142 |
| Neurocrine Biosciences, Inc. | 1 | $95 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Gilead | 1 | $26 |
| Eisai Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Bioxcel Therapeutics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$847
- ARISTADA$500
- Austedo XR$236
- CAPLYTA$223
- ARISTADA INITIO$125
- VRAYLAR$117
- UZEDY$116
- NUPLAZID$114
How this compares
$4,855 in reported general payments places this provider in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 24 | $327 |
| Hydroxyzine Pamoate | 23 | $256 |
| Aripiprazole | 14 | $189 |
| Trazodone Hcl | 23 | $106 |
| Fluoxetine Hcl | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Norman
- Amy BoggsNorman$15K
- Nicole HolzerNorman$12K
- Laura HallNorman$10K
- Melissa BelangerNorman$10K
- Paula RotherNorman$9K
- Teresa ShermanNorman$8K
- Vallie CopleyNorman$6K
- Renate WinninghamNorman$6K
- Craig PattonNorman$3K
- Meryl AaronEdmond$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.